舍曲林
重性抑郁障碍
帕罗西汀
内科学
5-羟色胺再摄取抑制剂
再摄取抑制剂
医学
血清素
血浆水平
内分泌学
心理学
精神科
抗抑郁药
受体
扁桃形结构
海马体
作者
Reiji Yoshimura,Hikaru Hori,Atsuko Ikenouchi-Sugita,Wakako Umene-Nakano,Asuka Katsuki,Kiyokazu Atake,Jun Nakamura
摘要
Objective We investigated the plasma levels of interleukin (IL)‐6 and 5‐HTT polymorphisms in patients with major depressive disorder (MDD). This is the first report, to our knowledge, of an investigation into the association between 5‐HTT gene polymorphism, plasma IL‐6 levels, and responses to selective serotonin reuptake inhibitors (SSRIs) in Japanese patients with MDD. Method One‐hundred and eighteen patients (51 male, 67 female) who met the DSM‐IV criteria for MDD were enrolled. Their ages ranged from 24 to 78 (mean ± SD = 44 ± 12) years. The patients were treated with SSRIs (paroxetine in 66 cases, sertraline in 42 cases) for 8 weeks. Results The plasma levels of IL‐6 were significantly higher in the SSRI responders than in the nonresponders ( p = 0.0328), and the changes in plasma IL‐6 levels correlated significantly with the changes in severity of depressive state ( p = .0.007). No difference was found in baseline and the changes in plasma IL‐6 levels between the patients with a 5‐HTT gene (5‐HTTLPR) L‐carrier and those with S/S. Conclusion These results suggest that the plasma levels of IL‐6 reflect the severity of MDD and that plasma IL‐6 levels might be another biological‐state marker for the depressive state. In addition, the 5‐HTTLPR polymorphism might be independent of plasma IL‐6 levels. Copyright © 2013 John Wiley & Sons, Ltd.
科研通智能强力驱动
Strongly Powered by AbleSci AI